Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds William Blair Initiates Coverage On POINT Biopharma Global with Outperform Rating

William Blair Initiates Coverage On POINT Biopharma Global with Outperform Rating

William Blair analyst Andy Hsieh initiates coverage on POINT Biopharma Global (NASDAQ:PNT) with a Outperform rating.

byBenzinga Newsdesk

July 6, 2022

1 minute read

William Blair analyst Andy Hsieh initiates coverage on POINT Biopharma Global (NASDAQ:PNT) with a Outperform rating.

Analyst Ratings

Expert Ratings For Caribou Biosciences

By Benzinga Insights

May 16, 2:01 PM

Ratings for Caribou Biosciences (NASDAQ:CRBU) were provided by 4 analysts in the past three months, showcasing a mix…

CRBU

Benchmark Upgrades NeoGenomics to Buy, Maintains $20 Price Target

By Benzinga Newsdesk

February 24, 7:33 AM

Benchmark analyst Bruce Jackson upgrades NeoGenomics (NASDAQ:NEO) from Hold to Buy and maintains $20 price target.

NEO

Analyst Ratings

Breaking Down California Bancorp: 4 Analysts Share Their Views

By Benzinga Insights

May 6, 11:00 AM

California Bancorp (NASDAQ:CALB) has been analyzed by 4 analysts in the last three months, revealing a diverse range…

CALB

HSBC UK Customers Hit by Online Banking Glitches During Black Friday Rush

By Anusuya Lahiri

November 24, 11:17 AM

HSBC Holdings Plc's (NYSE: HSBC) British customers face difficulties using the bank's mobile and online banking services, disrupting their Black Friday shopping experience.

HSBC

William Blair Initiates Coverage On POINT Biopharma Global with Outperform Rating

Related Posts

Expert Ratings For Caribou Biosciences

Benchmark Upgrades NeoGenomics to Buy, Maintains $20 Price Target

Breaking Down California Bancorp: 4 Analysts Share Their Views

HSBC UK Customers Hit by Online Banking Glitches During Black Friday Rush